Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. Impact of astroglial connexins on modafinil pharmacological properties. 2016 30:369–79.ĭuchêne A, Perier M, Zhao Y, Liu X, Thomasson J, Chauveau F, et al. Making the first anti-depressant: amphetamine in American medicine, 1929–1950. Clinical and practical considerations in the pharmacologic management of narcolepsy. Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, et al. Executive control of attention in narcolepsy. 2015 10:e0129386.īayard S, Croisier Langenier M, De C, Cock V, et al. Car crashes and central disorders of hypersomnolence: a French study. Pizza F, Jaussent I, Lopez R, Pesenti C, Plazzi G, Drouot X, et al. ![]() A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. ![]() Hypocretin (orexin) deficiency in human narcolepsy. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Darien: American Academy of Sleep Medicine 2014. International classification of sleep disorders. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Cataplexy–clinical aspects, pathophysiology and management strategy. This article reviewed treatment agents based on the neurobiology profiles particularly regulation of locus coeruleus (LC) norepinephrine (NE) neuron activity which appears to be central to the therapeutic ability of these agents.ĭauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. M Thorpy is a leader in pharmacotherapeutics as regards narcolepsy. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS.Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Silber MH, Krahn LE, Olson EJ, Pankratz VS. Gélineau J, De La Narcolepsie, Gazette des Hôpitaux Civils et Militaires 1880 part a, 53: 626–628, part b,635–637. Prevalence and incidence of narcolepsy in a US health care claims database, 2008–2010. Scheer D, Schwartz SW, Parr M, Zgibor J, Sanchez-Anguiano A, Rajaram L. Papers of particular interest, published recently, have been highlighted as: ![]() Further developments could conceivably be used for development of further novel therapeutic options. Novel treatments in narcolepsy may provide further patient-oriented individualized treatment. These agents include novel oxybate formulations (once-nightly low sodium ), a selective norepinephrine-reuptake inhibitor (AXS-12), and a product combining modafinil and an astroglial connexin inhibitor (THN102). The discovery of ORX deficiency in NT1 opened new therapeutic options oriented towards ORX-based therapies, especially nonpeptide ORX receptor agonists that are currently under development. Over the last decade, researchers have made great strides in understanding the biology of narcolepsy. This review aims to summarize the progress to date on this information on these agents. Currently, new treatments with varying mechanisms of action have recently been approved or are in clinical development. Narcolepsy is a chronic, disabling neurologic disorder characterized by excessive daytime sleepiness (EDS) and in up to 60% of patients, cataplexy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |